No Data
GNI Group: Financial Report - 24th Term (2024/01/01 - 2024/12/31)
GNI Group: Confirmation
GNI Group: Extraordinary Report
Announcement of the release of the thrombocytopenia (TP) treatment drug "Kangquxin" developed by Peking Continent Company.
GNIV Group, Inc. (hereinafter referred to as "the Company" including subsidiaries and affiliated companies as "the Company Group") announced that its main subsidiary, Peking Continental Pharmaceutical Co., Ltd. (hereinafter referred to as "Peking Continental"), has started sales of the drug Abatrombopag Mesylate Tablets "Kōkukushin" (English name: CONTIVA) after obtaining manufacturing and sales approval. Please refer to the press release of Peking Continental at the link below. 新闻动
The trading of major stocks may decrease, leading short-term funds to flow towards IPOs.
■ Since March 27 is the last day to hold rights for Dividends and benefits, interest is expected to turn towards Large Cap stocks in the Main Board, which may lead to a decrease in trading of key stocks in the Emerging Markets. On the other hand, the Growth Market 250 Index is clearly above the 25-day moving average, despite facing resistance at higher levels. It appears that a situation can be expected where attention is focused on the recent high of 693.92 points (February 13).
Regarding the resignation of our director and executive officer, the CFO.
GNI Group Inc. announced today that Tomoya Kitagawa, Executive Director and CFO, will resign from his current position at the 24th Annual General Meeting of Shareholders scheduled to be held on March 27, 2025. Comments from our CEO, Ian Luo, and Kitagawa regarding this matter will be included. - Comment from Ian Luo, Representative Executive Director and CEO: "It has been a pleasure for me to work with Mr. Tomoya Kitagawa since June 2023. His knowledge regarding IR, accounting, and management..."